•
EX
EXEL
Exelixis Inc
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
12.01B
Volume
1.58M
52W High
$49.62
52W Low
$31.90
Open
$0.00
Prev Close
$43.78
Day Range
0.00 - 0.00
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Latest News
InSilico Lands Drug Discovery Deal After Hong Kong IPO
Benzinga•Jan 15
2 Healthcare Stocks to Buy for 2026 and Beyond
The Motley Fool•Jan 8
2 Under-the-Radar Stocks to Buy Heading Into 2026
The Motley Fool•Dec 2
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
GlobeNewswire Inc.•Oct 31
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Benzinga•Oct 28
The Ultimate Biotech Stock to Buy With $50 Right Now
The Motley Fool•Oct 14
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight
GlobeNewswire Inc.•Oct 13
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
The Motley Fool•Sep 30